Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists. Issue 3 (11th December 2018)

• Record Type: Journal Article
• Authors: Eggebrecht, Lisa; Nagler, Markus; Göbel, Sebastian; Lamparter, Heidrun; Keller, Karsten; Wagner, Bianca; Panova‐Noeva, Marina; ten Cate, Vincent; Bickel, Christoph; Lauterbach, Michael; Espinola‐Klein, Christine; Hardt, Roland; Münzel, Thomas; Prochaska, Jürgen H.; Wild, Philipp S.
• Is Part Of: Journal of the American Geriatrics Society. Volume 67:Issue 3(2019)
• Page Start: 463
• Page End: 470
• Publication Date: 2018-12-11
• Subjects: anticoagulant drugs -- hemorrhage -- multimorbidity -- phenprocoumon -- polypharmacy; Geriatrics -- Periodicals; 618.97
• DOI: 10.1111/jgs.15712
• Languages: English
• ISSNs: 0002-8614

Abstract

Abstract : BACKGROUND: Although polypharmacy is associated with a negative clinical outcome in various settings and commonly observed in patients receiving oral anticoagulation therapy, evidence on the relevance for the clinical outcome of anticoagulated patients is currently limited. The aim of the study was to investigate the effect of polypharmacy on the clinical outcomes among patients taking phenprocoumon. DESIGN: Prospective cohort study. SETTING: Regular medical care. PARTICIPANTS: Information on 2011 individuals receiving vitamin K antagonists was available for analysis from the prospective multicenter thrombEVAL study. MEASUREMENTS: Data were obtained from clinical visits, computer‐assisted interviews, and laboratory measurements. Information on clinical outcome was obtained during a 3‐year follow‐up period and subsequently validated via medical records. RESULTS: The prevalence of polypharmacy (five drugs or more) was 84.1% (n = 1691). Quality of anticoagulation therapy assessed by time in therapeutic range was lower in individuals on five to eight drugs and nine drugs or more (70.7% and 64.7%, respectively) compared with subjects without polypharmacy (73.4%). In addition, a significantly higher variability of international normalized ratio measurements was found in the presence of polypharmacy. The cumulative incidence of bleeding, hospitalization, and all‐cause mortality, but not for thromboembolic events, increased across groups of medication. In adjusted Cox regression analysis, polypharmacy is an independent risk factor for bleeding (hazard ratio [HR]≥ 9 drugs vs 1‐4 drugs = 1.62; 95% confidence interval [CI] = 1.04‐2.52; p = .033); hospitalization (HR≥ 9 drugs vs 1‐4 drugs = 1.60; 95% CI = 1.26‐2.03; p < .001; and all‐cause mortality (HR≥ 9 drugs vs 1‐4 drugs = 2.16; 95% CI = 1.43‐3.27; p < .001) in a dose‐dependent relationship. Per additional drug, bleeding risk was increased by 4%. CONCLUSIONS: Polypharmacy influences the quality of anticoagulation therapy and translates into an elevated risk of adverse events in anticoagulated patients. This suggests that additional medication intake in such patients should be critically reviewed by physicians, and it highlights the importance of initiating investigations aimed at reducing multiple medication intake. J Am Geriatr Soc 67:463–470, 2019.